

Effect of plasma adsorption therapy in amyotrophic lateral sclerosis

Submission date 31/08/2017	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 20/09/2017	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 22/09/2017	Condition category Musculoskeletal Diseases	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol

Background and study aims

Amyotrophic lateral sclerosis (ALS) is a kind of progressive degenerative disease the deteriorates the spinal cord, brain stem and cortical motor neurons (the neurons from the brain). The average survival time from onset to death is 3-5 years. The average age of onset of ALS patients is about 55 years. It has the tendency of being inherited through families in about 5-20% of patients. The disease is not fully understood and there is no effective way to stop the progression of the disease. Plasma adsorption is a new blood purification technology widely used in the treatment of rheumatic diseases (those that affect joints and muscles) and some neurological diseases (diseases that attack the brain and connecting neurons), including myasthenia gravis (muscle weakness that comes and goes), multiple sclerosis and so on. The purpose of this study is to observe the efficacy of PA in the treatment of ALS and to explore its therapeutic mechanism.

Who can participate?

Patients with ALS .

What does the study involve?

Participants received plasma adsorption once a week for three successive times. One and a half times of the plasma volume of a patient is purified for each treatment. Participants are given medication to prevent anaphylaxis before treatment. Participants are followed up one week after treatment to see if there are any changes in their ALS symptoms.

What are the possible benefits and risks of participating?

Participants may benefit from the improvement of ALS due to plasma adsorption. There are potential risks of allergy, hemorrhage, circulatory disturbance and hemolysis during plasma adsorption. As this procedure have been maturely applied in clinical practice, risks can be controlled very low.

Where is the study run from?

The Third Affiliated Hospital of Southern Medical University (China)

When is the study starting and how long is it expected to run for?
August 2015 to December 2017

Who is funding the study?
Investigator initiated and funded (China)

Who is the main contact?
Dr. Zhou Shulu
1693494745@qq.com

Contact information

Type(s)
Public

Contact name
Dr Shulu Zhou

ORCID ID
<https://orcid.org/0000-0001-7870-6175>

Contact details
Department of Nephrology
Chengdu First People's Hospital
Sichuan
Chengdu
China
610041
+86 13926227269
1693494745@qq.com

Type(s)
Public

Contact name
Dr Bin Li

Contact details
Institute of Nephrology and Urology
The Third Affiliated Hospital of Southern Medical University
Guangdong
PR China
Guangzhou
China
510630
+86 13660196991
250001820@qq.com

Type(s)
Public

Contact name

Dr Hequn Zou

Contact details

Institute of Nephrology and Urology
The Third Affiliated Hospital of Southern Medical University
Guangdong
Guangzhou
China
510630
+86 13602825868
hequnzou@hotmail.com

Additional identifiers**Protocol serial number**

ZSL201611

Study information**Scientific Title**

A Short-term Outcome of Plasma Adsorption Therapy of Amyotrophic Lateral Sclerosis

Study objectives

Plasma adsorption method can improve ALS patients' clinical manifestations, ALSFR-S scores and level of serum superoxide dismutase, serum interleukin, serum creatine kinase and serum lactate dehydrogenase with comparison to before treatment.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Medical Ethics Committee The Third Affiliated Hospital of Southern Medical University China, 29 /08/2015, ref: 201508004

Primary study design

Interventional

Study design

Single-center one-arm before-and-after study

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Amyotrophic Lateral Sclerosis

Interventions

All patients received plasma adsorption once a week for three successive times. For each treatment, blood flow was 80-120mL/min and the slurry velocity was 1.5 L/h. One and a half

times of the Plasma volume of a patient was purified for each treatment. 20 mg dexamethasone and 25 mg phenergan were used to prevent anaphylaxis before treatment. Each participant was planned to be followed up for two years.

The following results of the treatment are evaluated:

1. Changes of clinical manifestations of ALS patients one week after treatment
2. Change of ALSFR-S scores after treatment
3. Changes of serum superoxide dismutase (SOD), serum interleukin -10 (IL-10), serum creatine kinase (CK) and serum lactate dehydrogenase (LDH) after treatment

Intervention Type

Procedure/Surgery

Primary outcome(s)

1. Clinical manifestations of ALS patients is measured using the physical examination at one week after treatment
2. Function evaluation is measured using ALSFR-S scores at one week after treatment
3. Serum creatine kinase (CK) and serum lactate dehydrogenase (LDH) at one week after treatment

Key secondary outcome(s)

No secondary outcome measures

Completion date

31/12/2017

Eligibility

Key inclusion criteria

1. Upper and lower motor neuron signs in three regions
2. Any age or gender

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

All

Sex

All

Key exclusion criteria

1. Allergic to membranes or pipelines of plasma separator and adsorber
2. Severe active bleeding or DIC; Systemic circulatory failure which do not respond well to treatment

3. Unstable myocardial or cerebral infarction, intracranial hemorrhage or severe brain edema with cerebral hernia

4. Incoordination due to psychonosema

Date of first enrolment

01/09/2015

Date of final enrolment

31/12/2015

Locations

Countries of recruitment

China

Study participating centre

The Third Affiliated Hospital of Southern Medical University

China

510000

Sponsor information

Organisation

The Third Affiliated Hospital of Southern Medical University

ROR

<https://ror.org/0050r1b65>

Funder(s)

Funder type

Not defined

Funder Name

Investigator initiated and funded

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and / or analysed during the current study is not expected to be made available due to protecting private information of participants.

IPD sharing plan summary

Not expected to be made available